Moleculin Biotech Reports Third Quarter 2026 Financial Results as Pivotal MIRACLE Trial Advances Toward Key Q1 2027 Data ReadoutGlobeNewsWire • Monday
Preclinical Data Show Annamycin Makes Pancreatic Cancer Responsive to Checkpoint Inhibitors, Opening a Combination Path with ImmunotherapiesGlobeNewsWire • 11/10/26
Moleculin Announces Acceptance of Annamycin Data for Presentation at the 2026 American Society of Hematology (ASH) Annual MeetingGlobeNewsWire • 11/04/26
Moleculin Completes Dosing Patients in Part A of Pivotal MIRACLE Trial; Comprehensive Data Readout on Track for Q1 2027GlobeNewsWire • 10/30/26
Moleculin Releases Next CEO Corner Segment Highlighting Recent Progress in Annamycin MIRACLE TrialGlobeNewsWire • 10/20/26
Moleculin Biotech to Participate in Advances in Oncology Panel at the 2026 Maxim Growth SummitGlobeNewsWire • 10/07/26
Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial, Keeping Program on Track for Q1 2027 Data ReadoutGlobeNewsWire • 09/29/26
Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular MedicineGlobeNewsWire • 09/28/26
Annamycin Turns “Cold” Pancreatic Tumors “Hot” in New Preclinical Data Presented at AACRGlobeNewsWire • 09/25/26
Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040GlobeNewsWire • 09/23/26
Moleculin to Showcase New Annamycin Data at AACR Conference on Pancreatic Cancer and Two European Scientific MeetingsGlobeNewsWire • 09/14/26
Moleculin Presentation from H.C. Wainwright Conference Now Available On-DemandGlobeNewsWire • 09/11/26
Moleculin CEO, Walter Klemp, Participates in the Virtual Investor “Why Now” On-Demand ConferenceGlobeNewsWire • 08/27/26
Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE TrialGlobeNewsWire • 08/14/26
Moleculin's MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed PatientsGlobeNewsWire • 07/31/26
Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor "What This Means" SegmentGlobeNewsWire • 07/06/26
Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than ControlGlobeNewsWire • 06/30/26
Independent Market Research Finds Strong Physician Intent to Prescribe Moleculin's Annamycin in Relapsed/Refractory AMLGlobeNewsWire • 06/05/26
Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor “What This Means” SegmentGlobeNewsWire • 06/04/26
Moleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline LimitsGlobeNewsWire • 05/29/26